Pancreatic Carcinoma

Oncology·MeSH: Pancreatic Neoplasms

Prevalence

0.5 / 100K

8 drugs in development·5 companies·5 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
lanreotide	GH Research PLC (GHRS)
Neoadjuvant olaparib	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(2)

Drug	Company
Olaparib	ENANTA PHARMACEUTICALS INC (ENTA)
ot-101	Oncotelic Therapeutics, Inc. (OTLC)

Phase 1/Phase 2(1)

Drug	Company
HCW9218	ImmunityBio, Inc. (IBRX)

Phase 4(3)

Drug	Company
Botulinum toxin type A	Revance Therapeutics, Inc. (RVNC)
Botulinum Toxin Type A 100U	Revance Therapeutics, Inc. (RVNC)
Botulinum Toxin Type A 200U	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 8 drugs in development for Pancreatic Carcinoma across 5 companies.

There are 5 clinical trials targeting Pancreatic Carcinoma tracked by BioSniper.

The estimated prevalence of Pancreatic Carcinoma is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.